System-Wide Analysis Reveals a Complex Network of Tumor-Fibroblast Interactions Involved in Tumorigenicity

English version České info

Many fibroblast-secreted proteins promote tumorigenicity, and several factors secreted by cancer cells have in turn been proposed to induce these proteins. It is not clear whether there are single dominant pathways underlying these interactions or whether they involve multiple pathways acting in parallel. Here, we identified 42 fibroblast-secreted factors induced by breast cancer cells using comparative genomic analysis. To determine what fraction was active in promoting tumorigenicity, we chose five representative fibroblast-secreted factors for in vivo analysis. We found that the majority (three out of five) played equally major roles in promoting tumorigenicity, and intriguingly, each one had distinct effects on the tumor microenvironment. Specifically, fibroblast-secreted amphiregulin promoted breast cancer cell survival, whereas the chemokine CCL7 stimulated tumor cell proliferation while CCL2 promoted innate immune cell infiltration and angiogenesis. The other two factors tested had minor (CCL8) or minimally (STC1) significant effects on the ability of fibroblasts to promote tumor growth. The importance of parallel interactions between fibroblasts and cancer cells was tested by simultaneously targeting fibroblast-secreted amphiregulin and the CCL7 receptor on cancer cells, and this was significantly more efficacious than blocking either pathway alone. We further explored the concept of parallel interactions by testing the extent to which induction of critical fibroblast-secreted proteins could be achieved by single, previously identified, factors produced by breast cancer cells. We found that although single factors could induce a subset of genes, even combinations of factors failed to induce the full repertoire of functionally important fibroblast-secreted proteins. Together, these results delineate a complex network of tumor-fibroblast interactions that act in parallel to promote tumorigenicity and suggest that effective anti-stromal therapeutic strategies will need to be multi-targeted.

Vyšlo v časopise: System-Wide Analysis Reveals a Complex Network of Tumor-Fibroblast Interactions Involved in Tumorigenicity. PLoS Genet 9(9): e32767. doi:10.1371/journal.pgen.1003789
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003789

Souhrn

Zdroje

1. EgebladM, NakasoneES, WerbZ (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18: 884–901.

2. CaseyT, BondJ, TigheS, HunterT, LintaultL, et al. (2009) Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat 114: 47–62.

3. FinakG, BertosN, PepinF, SadekovaS, SouleimanovaM, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518–527.

4. MaXJ, DahiyaS, RichardsonE, ErlanderM, SgroiDC (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11: R7.

5. AllinenM, BeroukhimR, CaiL, BrennanC, Lahti-DomeniciJ, et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17–32.

6. FerraraN, GerberHP, LeCouterJ (2003) The biology of VEGF and its receptors. Nat Med 9: 669–676.

7. ElenbaasB, WeinbergRA (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 264: 169–184.

8. GiannoniE, BianchiniF, MasieriL, SerniS, TorreE, et al. (2010) Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 70: 6945–6956.

9. KumarS, KishimotoH, ChuaHL, BadveS, MillerKD, et al. (2003) Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol 163: 2531–2541.

10. EgebladM, LittlepageLE, WerbZ (2005) The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 70: 383–388.

11. PolyakK, KalluriR (2010) The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2: a003244.

12. StueltenCH, BuschJI, TangB, FlandersKC, OshimaA, et al. (2010) Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One 5: e9832.

13. OrimoA, GuptaPB, SgroiDC, Arenzana-SeisdedosF, DelaunayT, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335–348.

14. ChengN, ChytilA, ShyrY, JolyA, MosesHL (2007) Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res 67: 4869–4877.

15. ZhangW, MatrisianLM, HolmbeckK, VickCC, RosenthalEL (2006) Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 6: 52.

16. PazolliE, LuoX, BrehmS, CarberyK, ChungJJ, et al. (2009) Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 69: 1230–1239.

17. TsuyadaA, ChowA, WuJ, SomloG, ChuP, et al. (2012) CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 72: 2768–2779.

18. CoppeJP, DesprezPY, KrtolicaA, CampisiJ (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5: 99–118.

19. ErezN, TruittM, OlsonP, ArronST, HanahanD (2010) Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 17: 135–147.

20. KojimaY, AcarA, EatonEN, MellodyKT, ScheelC, et al. (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 107: 20009–20014.

21. KalluriR, ZeisbergM (2006) Fibroblasts in cancer. Nat Rev Cancer 6: 392–401.

22. MartinTA, ParrC, DaviesG, WatkinsG, LaneJ, et al. (2003) Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24: 1317–1323.

23. HollidayDL, HughesS, ShawJA, WalkerRA, JonesJL (2007) Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 9: R67.

24. KimBG, GaoMQ, ChoiYP, KangS, ParkHR, et al. (2012) Invasive breast cancer induces laminin-332 upregulation and integrin beta4 neoexpression in myofibroblasts to confer an anoikis-resistant phenotype during tissue remodeling. Breast Cancer Res 14: R88.

25. StokesJB, AdairSJ, Slack-DavisJK, WaltersDM, TilghmanRW, et al. (2011) Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther 10: 2135–2145.

26. Sanz-MorenoV, GaggioliC, YeoM, AlbrenguesJ, WallbergF, et al. (2011) ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 20: 229–245.

27. BauerM, SuG, CasperC, HeR, RehrauerW, et al. (2010) Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 29: 1732–1740.

28. IslamSA, ChangDS, ColvinRA, ByrneMH, McCullyML, et al. (2011) Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells. Nat Immunol 12: 167–177.

29. BoldtHB, ConoverCA (2011) Overexpression of pregnancy-associated plasma protein-A in ovarian cancer cells promotes tumor growth in vivo. Endocrinology 152: 1470–1478.

30. ChimSM, QinA, TicknerJ, PavlosN, DaveyT, et al. (2011) EGFL6 promotes endothelial cell migration and angiogenesis through the activation of extracellular signal-regulated kinase. J Biol Chem 286: 22035–22046.

31. BogunovicD, ByunM, DurfeeLA, AbhyankarA, SanalO, et al. (2012) Mycobacterial Disease and Impaired IFN-gamma Immunity in Humans with Inherited ISG15 Deficiency. Science

32. RatajczakMZ, RecaR, WysoczynskiM, YanJ, RatajczakJ (2006) Modulation of the SDF-1-CXCR4 axis by the third complement component (C3)–implications for trafficking of CXCR4+ stem cells. Exp Hematol 34: 986–995.

33. RosasM, ThomasB, StaceyM, GordonS, TaylorPR (2010) The myeloid 7/4-antigen defines recently generated inflammatory macrophages and is synonymous with Ly-6B. J Leukoc Biol 88: 169–180.

34. HorakER, LeekR, KlenkN, LeJeuneS, SmithK, et al. (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120–1124.

35. SugimotoH, MundelTM, KieranMW, KalluriR (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5: 1640–1646.

36. JungDW, CheZM, KimJ, KimK, KimKY, et al. (2010) Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int J Cancer 127: 332–344.

37. SternlichtMD, SunnarborgSW (2008) The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia 13: 181–194.

38. LiuG, YangG, ChangB, Mercado-UribeI, HuangM, et al. (2010) Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 102: 812–827.

39. FernandezEJ, LolisE (2002) Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 42: 469–499.

40. Ronnov-JessenL, PetersenOW (1993) Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68: 696–707.

41. ChouJ, LinJH, BrenotA, KimJW, ProvotS, et al. (2013) GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 15: 201–213.